Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Rebamipide Is Most Frequently Prescribed Drug by Generic Name: Apollo Medical Survey
August 3, 2012
- Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
- Otsuka Files for Additional Indication for Samsca for Fluid Retention with Liver Cirrhosis
August 2, 2012
- BMKK, Pfizer Promote Disease Education on Chronic Hepatitis B
August 2, 2012
- Shionogi Launches Endoxan Powder Aimed at Pediatric Patients
August 2, 2012
- AnGes MG to Initiate Domestic PI/II Trials for Collategene
August 2, 2012
- Torii Initiates PII/PIII Clinical Studies in Japan for Desensitization Therapy for House Dust Mite Induced Allergies
August 2, 2012
- Daiichi Sankyo’s Apr-Jun Sales Up 4.7%, Bolstered by Ranbaxy
August 1, 2012
- Iwasaki of Takeda Shows Confidence in Achieving Sales Target of Nesina with Rapid Growth
August 1, 2012
- Astellas, Tokyo Institute of Technology to Start Joint Drug Discovery Research for Neglected Tropical Diseases
July 31, 2012
- Shionogi Files NDA for Fixed-Dose Combination of Irbetan, Fluitran
July 31, 2012
- Nycomed Drives Up Takeda’s April-June Sales by 11.5%, but Operating Profits Decline
July 31, 2012
- Nearly 60% of Doctors Feel Generics Might Be Less Effective than Original Drugs: Survey
July 31, 2012
- Research Subsidiary of Eisai to Move to Kobe Strategic Zone
July 31, 2012
- Major Domestic Makers’ Vaccine Business Gains Momentum; Addition of New Vaccines to Public Vaccination Program Could Spark Debate Over Funding
July 31, 2012
- Afatinib Significantly Improves PFS in Japanese NSCLC Patients: BI Japan
July 31, 2012
- Kyowa Kirin Launches Apokyn for Parkinson’s Disease
July 31, 2012
- Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
- Takeda Resubmits NDAs to US FDA for Alogliptin
July 31, 2012
- DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…